Source link : https://www.newshealth.biz/health-news/weekly-insulin-efsitora-noninferior-to-daily-degludec-in-type-1-type-2-diabetes/
An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky for those with type 1 diabetes, the phase III QWINT-2 and -5 trials showed. In insulin-naive patients with type 2 diabetes enrolled in QWINT-2, average HbA1c levels decreased from 8.21% at baseline to 6.97% at week […]
Author : News Health
Publish date : 2024-09-10 19:31:35
Copyright for syndicated content belongs to the linked Source.